Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 245 bp insertion in exon3 and Insertion of the selection cassette in exon3.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EXOC7, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EXOC7 also known as Exocyst Complex Component 7 is a part of the exocyst complex involved in the regulation of vesicle trafficking. This protein weighs approximately 76 kDa and functions by facilitating the fusion of vesicles with the plasma membrane. It is generally expressed in various tissue types but shows higher levels in lung and brain tissues. EXOC7 often works with other components of the exocyst complex to carry out its role in cellular trafficking.
Biological function summary
EXOC7 plays a significant role in exocyst-mediated processes acting as a critical component of the exocyst complex. This multi-protein complex is essential for targeting secretory vesicles to specific docking sites in the plasma membrane. EXOC7 is involved in processes like cell polarity migration and even in the maintenance of tight junctions. Through its interactions with other exocyst components it aids in the spatial organization of the cell influencing overall cellular architecture and functionality.
Pathways
EXOC7 integrates into exocytosis and cell signaling pathways. It particularly plays a role in the exocytosis pathway which is essential for secretion and cell-surface receptor recycling. EXOC7 interacts with other exocyst complex proteins such as SEC10 and SEC15 promoting efficient vesicle tethering and fusion events. Additionally it links to the ARF6-dependent pathways that affect actin cytoskeleton remodeling demonstrating its importance in cell movement and structural remodeling.
EXOC7's proper function is essential for normal cellular processes and its dysregulation has connections to type 2 diabetes and certain cancers. In type 2 diabetes misregulated exocyst complex activities including those involving EXOC7 can disrupt insulin secretion. In cancer altered expression or function of the exocyst complex may contribute to metastasis due to its role in cell adhesion and migration. EXOC7's interaction with other proteins such as EXOC3L1 and EXOC5 could play a significant role in these disease mechanisms highlighting its potential as a target for therapeutic intervention.
